Pimonidazole

Pimonidazole

SCHEMBL51977

O=[N+]([O-])c1nccn1CC(O)CN1CCCCC1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.63
MEN1 O00255 1/20 0.45
CYP2C19 P33261 2/20 0.42
LMNA P02545 1/20 0.42
THRB P10828 1/20 0.42
RAD52 P43351 1/20 0.41
CA12 O43570 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA9 Q16790 3/20 0.40
ATM Q13315 1/20 0.40
TYMP P19971 3/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP2D6 P10635 3/20 0.40
PLK1 P53350 2/20 0.39
CYP3A4 P08684 1/20 0.39
OPRK1 P41145 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pimonidazole SCHEMBL11390660 0.99 KMT2A (0.62) KMT2AMEN1CYP2C19LMNATHRB
SCHEMBL11352268 0.99 KMT2A (0.64) KMT2AMEN1CYP2C19LMNATHRB
Hydrochloric Acid SCHEMBL11376105 0.97 KMT2A (0.63) KMT2AMEN1CYP2C19LMNATHRB
SCHEMBL8895819 0.93 KMT2A (0.67) KMT2ACYP2C19LMNATHRBRAD52
SCHEMBL8855534 0.93 KMT2A (0.67) KMT2ACYP2C19LMNATHRBRAD52
SCHEMBL367134 0.93 KMT2A (0.67) KMT2ACYP2C19LMNATHRBRAD52
SCHEMBL12396375 0.87 KMT2A (0.78) KMT2AMEN1CYP2C19LMNATHRB
SCHEMBL11379553 0.87 KMT2A (0.64) KMT2AMEN1CYP2C19LMNATHRB
SCHEMBL11350180 0.87 KMT2A (0.60) KMT2ACYP2C19LMNATHRBCA12
SCHEMBL15214897 0.87 KMT2A (0.60) KMT2ACYP2C19LMNATHRBRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3097 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250295869-A1 ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER THRESHOLD PHARMACEUTICALS, INC. 2025-09-25 US claimed
US-20250222066-A1 COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION UNIVERSITY OF UTAH RESEARCH FOUNDATION 2025-07-10 US claimed
EP-4547023-A2 COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION University of Utah Research Foundation (US) 2025-05-07 EP claimed
WO-2024259358-A2 MODULATION OF FUSOBACTERIUM NUCLEATUM SUBSPECIES ANIMALIS CLADE 2 MICROBES FRED HUTCHINSON CANCER CENTER (US) 2024-12-19 WO claimed
EP-4086250-B1 MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2024-12-11 EP claimed
WO-2024216250-A1 METHOD FOR NON-INVASIVE HYPOXIA DETECTION BIOVENTURES, LLC (US) 2024-10-17 WO claimed
EP-4419094-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS Edison Oncology (US) 2024-08-28 EP claimed
WO-2024085926-A2 COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2024-04-25 WO claimed
WO-2023069727-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS EDISON ONCOLOGY (US) 2023-04-27 WO claimed
US-20220249522-A1 Hypoxia Targeting Compositions and Combinations Thereof with a PARP Inhibitor and Methods of Use Thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-08-11 US claimed
US-20020122768-A1 Stable radiopharmaceutical compositions and methods for preparation thereof LANTHEUS MEDICAL IMAGING, INC. 2002-09-05 US claimed
WO-2002004030-A2 STABLE RADIOPHARMACEUTICAL COMPOSITIONS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-01-17 WO claimed
WO-2001097860-A2 PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS FOR USE IN COMBINATION THERAPY BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-27 WO claimed
WO-2001097861-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-27 WO claimed
WO-2001097848-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-27 WO claimed
WO-2001098294-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-27 WO claimed
WO-2001060820-A2 MATRIX METALLOPROTEINASE INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-08-23 WO claimed
US-5674693-A Derivatives of 2-nitro-imidazoles as hypoxic cell markers NATURAL PHARMACIA INTERNATIONAL INC. (US) 1997-10-07 US claimed
EP-0000928-B1 NITROIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS WELL AS THEIR PREPARATION F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-03-18 EP claimed
EP-0000928-A1 Nitroimidazoles and pharmaceutical compositions containing them as well as their preparation F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1979-03-07 EP claimed